MATINAS BIOPHARMA HOLDINGS, INC. — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1f9623da-7c12-407b-a0f3-aef2c415ef94/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-10.3M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-014132 |
| FY 2024 | $-24.3M | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-004882 |
| FY 2023 | $-22.9M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011493 |
| FY 2022 | $-21.0M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-007726 |
| FY 2021 | $-23.3M | 2021-01-01 – 2021-12-31 | evidence 0001493152-23-007726 |
| FY 2020 | $-22.4M | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-006979 |
| FY 2019 | $-17.4M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-003558 |
| FY 2018 | $-14.1M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-004560 |
| FY 2017 | $-15.5M | 2017-01-01 – 2017-12-31 | evidence 0001493152-18-003518 |
| FY 2016 | $-7.6M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-018184 |
| FY 2015 | $7.1M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-134200 |
| FY 2014 | $10.2M | 2014-01-01 – 2014-12-31 | evidence 0001144204-15-048999 |
| FY 2013 | $-6.0M | 2011-08-11 – 2014-03-31 | evidence 0001144204-14-036135 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
MATINAS BIOPHARMA HOLDINGS, INC. — all facts · Revenue · Operating Income